A5008759669- SARS-CoV-2 and COVID-19 Research
- Vaccine Coverage and Hesitancy
- Space exploration and regulation
- COVID-19 epidemiological studies
- COVID-19 Clinical Research Studies
- Viral gastroenteritis research and epidemiology
- COVID-19 and healthcare impacts
- Heparin-Induced Thrombocytopenia and Thrombosis
- Satellite Communication Systems
- COVID-19 and Mental Health
- Public Health Policies and Education
- Intramuscular injections and effects
- Healthcare cost, quality, practices
- Travel-related health issues
- SARS-CoV-2 detection and testing
- Telemedicine and Telehealth Implementation
- Spacecraft Design and Technology
- Healthcare Policy and Management
- Geriatric Care and Nursing Homes
- Pneumonia and Respiratory Infections
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Hepatitis B Virus Studies
- Distributed systems and fault tolerance
- Mental Health Treatment and Access
- Food Security and Health in Diverse Populations
Centers for Disease Control and Prevention
2020-2025
National Center for Immunization and Respiratory Diseases
2020-2024
Medical University of South Carolina
2015-2024
National Center for Victims of Crime
2015-2024
Johns Hopkins University
2018-2022
University of Pittsburgh
2022
Epidemic Intelligence Service
2020-2021
Computer Emergency Response Team
2011-2021
Louisiana State Department of Health and Hospitals
2021
Brunswick (United States)
2021
Coronavirus disease 2019 (COVID-19) is a caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in China December, 2019. In January, 2020, state, local, and federal public health agencies investigated the case of COVID-19 Illinois, USA.Patients with confirmed were defined as those positive SARS-CoV-2 test. Contacts people exposure to patient on or after patient's symptom onset date. underwent active monitoring for 14 days following their last exposure. who...
In December 2020, the Food and Drug Administration (FDA) issued Emergency Use Authorizations (EUAs) for Pfizer-BioNTech COVID-19 (BNT162b2) vaccine Moderna (mRNA-1273) vaccine,† Advisory Committee on Immunization Practices (ACIP) interim recommendations their use in persons aged ≥16 years ≥18 years, respectively.§ May 2021, FDA expanded EUA to include adolescents 12-15 years; ACIP recommends that all ≥12 receive a vaccine. Both vaccines are mRNA encoding stabilized prefusion spike...
This report describes the interim recommendation made by Advisory Committee on Immunization Practices December 12, 2020, for use of Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years.
An estimated 30 million passengers are transported on 272 cruise ships worldwide each year* (1). Cruise bring diverse populations into proximity for many days, facilitating transmission of respiratory illness (2). SARS-CoV-2, the virus that causes coronavirus disease (COVID-19) was first identified in Wuhan, China, December 2019 and has since spread to at least 187 countries territories. Widespread COVID-19 been reported as well (3). Passengers certain ship voyages might be aged ≥65 years,...
The first vaccines for prevention of coronavirus disease 2019 (COVID-19) in the United States were authorized emergency use by Food and Drug Administration (FDA) (1) recommended Advisory Committee on Immunization Practices (ACIP) December 2020.* However, demand COVID-19 is expected to exceed supply during months national vaccination program. ACIP advises CDC population groups circumstances vaccine use.† On 1, that 1) health care personnel§ 2) residents long-term facilities¶ be offered first,...
The emergence of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), has led to a global pandemic disrupted all sectors society. Less than 1 year after SARS-CoV-2 genome was first sequenced, an application* for Emergency Use Authorization candidate vaccine been filed with Food and Drug Administration (FDA). However, even if one or more candidates receive authorization emergency use, demand COVID-19 is expected exceed supply during months national vaccination program....
On December 18, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Moderna COVID-19 (mRNA-1273) vaccine (ModernaTX, Inc; Cambridge, Massachusetts), a lipid nanoparticle-encapsulated, nucleoside-modified mRNA encoding stabilized prefusion spike glycoprotein of SARS-CoV-2, virus that causes coronavirus disease 2019 (COVID-19) (1). This is second authorized under EUA prevention in United States (2). Vaccination with consists 2 doses (100 μg, 0.5 mL...
Since August 2019, CDC, the Food and Drug Administration (FDA), state local health departments, public clinical stakeholders have been investigating a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) (1). This report updates patient demographic characteristics, self-reported substance use, hospitalization dates for EVALI patients reported to CDC by states, as well distribution emergency department (ED) visits related products analyzed through National...
In December 2019, a cluster of cases pneumonia emerged in Wuhan City central China's Hubei Province. Genetic sequencing isolates obtained from patients with identified novel coronavirus (2019-nCoV) as the etiology (1). As February 4, 2020, approximately 20,000 confirmed had been China and an additional 159 23 other countries, including 11 United States (2,3). On January 17, CDC U.S. Department Homeland Security's Customs Border Protection began health screenings at airports to identify ill...
The Advisory Committee on Immunization Practices concluded that the benefits of resuming Janssen COVID-19 vaccination among persons aged ≥18 years outweighed risks and reaffirmed its interim recommendation under FDA's Emergency Use Authorization, which includes a new warning for rare clotting events women 18–49 years.
the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Janssen COVID-19 (Ad.26.COV2.S) vaccine (Janssen Biotech, Inc, a Pharmaceutical company, Johnson & Johnson; New
Three COVID-19 vaccines are currently approved under a Biologics License Application (BLA) or authorized an Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) recommended for primary vaccination Advisory Committee on Immunization Practices (ACIP) in United States: 2-dose mRNA-based Pfizer-BioNTech/Comirnaty Moderna single-dose adenovirus vector-based Janssen (Johnson & Johnson) vaccine (1,2) (Box 1). In August 2021, FDA amended EUAs two mRNA to allow additional dose...
An estimated 2.1 million U.S. adults are housed within approximately 5,000 correctional and detention facilities† on any given day (1). Many facilities face significant challenges in controlling the spread of highly infectious pathogens such as SARS-CoV-2, virus that causes coronavirus disease 2019 (COVID-19). Such include crowded dormitories, shared lavatories, limited medical isolation resources, daily entry exit staff members visitors, continual introduction newly incarcerated or detained...
In May 2021, after a systematic review of all available data, the Advisory Committee on Immunization Practices made an interim recommendation for use Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12–15 years prevention COVID-19.
This report describes the Advisory Committee on Immunization Practices recommendation for seasonal administration of a single dose RSV vaccine during weeks 32 through 36 pregnancy to help prevent severe illness in infants younger than 6 months.
COVID-19 vaccines protect against severe COVID-19-associated outcomes, including hospitalization and death. As SARS-CoV-2 has evolved, waning vaccine effectiveness been noted, formulations policies have updated to provide continued protection illness death from COVID-19. Since September 2022, bivalent mRNA recommended in the United States, but variants these are no longer circulating widely. On 11, 2023, Food Drug Administration (FDA) approved (2023-2024 Formula) by Moderna Pfizer-BioNTech...
On February 27, 2021, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for adenovirus-vectored COVID-19 vaccine (Janssen Biotech, Inc., a Janssen Pharmaceutical company, Johnson & Johnson), on 28, Advisory Committee Immunization Practices (ACIP) interim recommendation its use as single-dose primary vaccination in persons aged ≥18 years (1,2). April 13, CDC FDA recommended pause of after reports thrombosis with thrombocytopenia syndrome (TTS), rare condition...
COVID-19 vaccination provides additional protection against severe COVID-19-associated illness and death. Since September 2023, 2023-2024 Formula monovalent XBB.1-strain vaccines have been recommended for use in the United States all persons aged ≥6 months. However, SARS-CoV-2 continues to evolve, since winter 2023-2024, Omicron JN.1 lineage strains of SARS-CoV-2, including strain KP.2 strain, widely circulating States. Further, vaccine effectiveness is known wane. On June 27, 2024, Advisory...
COVID-19 remains an important public health threat, despite overall decreases in COVID-19-related severe disease since the start of pandemic. COVID-19-associated hospitalization rates remain higher among adults aged ≥65 years relative to younger adults, adolescents, and children; during October 2023-January 2024, 67% all hospitalizations were persons years. On September 12, 2023, CDC's Advisory Committee on Immunization Practices (ACIP) recommended updated (2023-2024 Formula) vaccination...
Abbreviations: COVID-19 = coronavirus disease 2019; HCP health care personnel.* Health personnel: paid and unpaid persons serving in settings who have the potential for direct or indirect exposure to patients infectious materials; other essential workers: person conduct operations vital continuing critical infrastructure, such as food, agriculture, transportation, education, law enforcement; adults with high risk medical conditions: one more high-risk conditions, obesity, diabetes,...
This report provides a nationwide comparison of clinical characteristics e-cigarette, or vaping, product use–associated lung injury patients who were rehospitalized died after hospital discharge
CDC, the Food and Drug Administration (FDA), state local health departments, public clinical stakeholders continue to investigate a nationwide outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) (1). EVALI patients in Illinois, Utah, Wisconsin acquired tetrahydrocannabinol (THC)-containing products primarily from informal sources (2,3). This report updates demographic characteristics self-reported THC- nicotine-containing derived patient data reported CDC by...
Telepsychotherapy (also referred to as telehealth or telemental health), the use of videoconferencing deliver psychotherapy services, offers an innovative way address significant gaps in access care and is being used a variety treatments for youth. Although recent research has supported effectiveness delivery interventions children, literature focused very little on childhood posttraumatic stress disorder. This pilot study examined feasibility potential trauma-focused cognitive- behavioral...
On June 17, 2022, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) amendments for mRNA-1273 (Moderna) COVID-19 vaccine use in children aged 6 months-5 years, administered as 2 doses (25 µg [0.25 mL] each), 4 weeks apart, BNT162b2 (Pfizer-BioNTech) months-4 3 (3 [0.2 at intervals of between 1 ≥8 3. 18, Advisory Committee on Immunization Practices (ACIP) separate interim recommendations Moderna years Pfizer-BioNTech prevention COVID-19.* Both vaccines met...
Throughout the national public health emergency declared in response to COVID-19 pandemic, CDC, guided by Advisory Committee on Immunization Practices (ACIP), has offered evidence-based recommendations for use of vaccines U.S. populations after each regulatory action Food and Drug Administration (FDA). During August 2022-April 2023, FDA amended its Emergency Use Authorizations (EUAs) authorize a single, age-appropriate, bivalent vaccine dose (i.e., containing components from ancestral...